Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG)
Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) represented a move of 0 percent or $0.01 per share and closed its previous day trading session at $0.49. 0 Shares were traded in the last trading session with an Average Volume of 1.36 Million Shares. The stock currently has a Market Capitalization of 21.86 Million.
EyeGate Pharmaceuticals, Inc. is a pharmaceutical company which is engaged in developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The company’s technology consists of EyeGate(R) II Delivery System. Its product pipeline includes EGP-437 which is in different clinical stage. EyeGate Pharmaceuticals, Inc. is based in WALTHAM, MA.
The stock traded between $0.280 and $1.340 over 1-Year time period showing its price to sales ratio of 12.86. Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $19.59 and 200-Day Simple Moving Average of $-1.42. Its Price to Free Cash Flow is 0 and Price to Book of 1.87.
Analyst’s recommended the stock as 2 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) reported its Actual EPS of $-0.07/share. The analysts offering Earnings Estimates for the company were believing that Eyegate Pharmaceuticals, Inc. could bring EPS of $-0.08/share. The difference between Actual EPS and Estimated EPS was 0.01 Percent. Thus showing an Earnings Surprise of 12.5 Percent.
NanoViricides, Inc. (NYSE:NNVC)
In the last trading session, NanoViricides, Inc. (NYSE:NNVC) added its value by 0% closing at the price of $0.36. The stock currently has market capitalization of 25.21 Million, with average volume of 115.41 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently NanoViricides, Inc. (NYSE:NNVC) is showing beta of 0.22. This particular value of beta suggests that NanoViricides, Inc. (NYSE:NNVC) has historically moved 22% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for NanoViricides, Inc. (NYSE:NNVC) is at $-0.13.
The stock currently has RSI of 54.21. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
NanoViricides, Inc. is a development stage company focused on creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. It also focuses on the development of drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides, Inc. is headquartered in West Haven, Connecticut.
NanoViricides, Inc. (NYSE:NNVC) topped its 52-week high price of $1.230 on 12/07/17 and 52-Week Low Price of $0.250 on 10/24/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 7.61% and monthly volatility of 12.64% respectively.